Last reviewed · How we verify
NCT03303508
Measurement of Anti-dsDNA by Both CLIFT & ELISA
NA trial testing anti-ds DNA in Antiphospholipid Syndrome in 100 participants. Status unknown.
1 September 2019
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 1 September 2018 |
| Primary completion | 1 September 2019 |
| Estimated completion | 1 October 2019 |
Drugs / interventions tested
- anti-ds DNA
Conditions studied
- Antiphospholipid Syndrome — all drugs for Antiphospholipid Syndrome →
Sponsor
Assiut University
Who can join
Adults 20 to 70, any sex, with Antiphospholipid Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
detection of anti-ds DNA in patients with rheumatic diseases by two methodes : immunofluorescence \& ELISA
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03303508
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Antiphospholipid Syndrome
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07236762 — An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · Phase 1 · recruiting
- NCT07236801 — Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases · Phase 1 · recruiting
- NCT07163338 — Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) · NA · recruiting
- NCT06828042 — Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases · Phase 1, PHASE2 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03303508 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 6 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03303508.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing